Methods of treating metabolic disorders with an FGF21 variant
US9266935B2 · kind B2 · utility
11Cited by
1References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 24, 2015 |
| Grant date | Feb 23, 2016 |
| Priority date | — |
| Expiry date | Feb 24, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.